| Affymax Shares Fall on Drug's Heart Safety Concerns - BusinessWeek |
|
|
BusinessWeekIn the results released today, 22 percent of non-dialysis patients taking Hematide had a cardiovascular complication, compared with 17 percent of those ...Affymax drops as drug trials raise heart concerns ReutersAffymax Shares Plunge On Hematide Study Data Wall Street JournalAffymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... read more |